Strong Sales, Earnings Send Exelixis Shares Higher

Exelixis (EXEL) is up 43.5% over the past year and 26% YTD, supported by institutional inflows. In Q2 2026 it reported $629M quarterly revenue (including $573M from cabozantinib, +10% YoY), $212M GAAP net income ($0.82/diluted share), and $1.4B cash, while repurchasing $312M in the quarter. EPS is estimated to rise +16% this year, reinforcing a bullish fundamental and positioning backdrop.

Analysis

EXEL is behaving more like a self-funding biotech than a pure clinical optionality story, and that matters in a higher-for-longer rate regime. The combination of cash generation and repurchases creates a mechanical bid for the stock, while also reducing float and making incremental institutional demand more price-sensitive than fundamentals alone would suggest. Near term, that can keep the tape constructive even without a fresh catalyst, but the market will eventually ask whether the core asset can keep comping enough to justify a growth multiple rather than a mature franchise multiple.

The real second-order effect is capital allocation within oncology. Profitable, cash-returning names like EXEL should continue to siphon money from the lower-quality end of XBI, where funding dependence and dilution remain the hidden cost of waiting for data. If investors keep rewarding balance-sheet strength over pipeline breadth, the relative winner is not just EXEL but the broader cohort of profitable specialty pharma with visible free cash flow; the loser is pre-profit oncology exposure that needs the capital markets open.

The main risk is that the flow signal is backward-looking and can persist longer than the actual earnings acceleration. If cabozantinib growth slows to low-single digits or management leans harder on buybacks instead of pipeline investment, the stock could rerate from a momentum compounder into a cash-cow multiple, capping upside. The key falsifier over the next 1-3 quarters is any guidance or quarterly revenue inflection that shows the franchise is plateauing; if that happens, the institutional support narrative likely fades fast, even if the absolute business remains profitable.

Key Decisions for Investors

• Long EXEL vs short XBI for a 1-3 month relative-value trade: the spread should benefit if capital keeps rotating toward profitable oncology and away from dilutive biotech; stop if EXEL loses its recent relative strength or XBI outperforms on a risk-on tape.
• If entering outright long, use a staggered approach on pullbacks rather than chasing after the flow-driven move; the setup is better as a grind than a breakout, with upside mainly from continued buyback absorption over the next 1-2 quarters.
• Watch for any quarterly sign of cabozantinib deceleration; if revenue growth slips materially, reduce exposure because the market will likely compress the multiple before the buyback can offset it.
• As a hedge against crowded biotech factor exposure, consider trimming lower-quality names in XBI/IBB with negative free cash flow and pairing into EXEL or other cash-generative oncology names; this works best if rates remain elevated.
• No aggressive options expression unless implied volatility is cheap: a modest call spread only makes sense if you expect another quarter of institutional buying plus stable guidance; otherwise the risk/reward is too dependent on flow persistence.